Aras Toker

5PUBLICATIONS
32CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Agricultural molecular engineering of nucleic acids and proteinsInnate immunityMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 11, 2025
Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects.

Michela Capello, Angelica Sette, Theo Plantinga

|Nov 15, 2022
Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.

Alexander Muik, Bonny Gaby Lui, Maren Bacher

|Sep 20, 2022
Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5.

Alexander Muik, Bonny Gaby Lui, Maren Bacher

|Jun 10, 2022
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.

Alexander Muik, Homer C Adams 3rd, Friederike Gieseke

|Feb 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.

Alexander Muik, Elena Garralda, Isil Altintas

Pageof 1

Frequent Collaborators

3 joint publications

Alexander Muik

2 joint publications

Katharina Grikscheit

2 joint publications

Saskia M Burm

2 joint publications

Orkun Ozhelvaci